(Q34732988)

4 August 2017

1 reference

title

Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation (English)

1 reference

4 August 2017

1

1 reference

4 August 2017

2

Ana Castro

1 reference

4 August 2017

Isabel Dorronsoro

3

1 reference

PubMed ID

12111750

4 August 2017

Mercedes Alonso

series ordinal

4

1 reference

PubMed ID

12111750

4 August 2017

language of work or name

1 reference

1 July 2002

1 reference

Medicinal Research Reviews

4 August 2017

1 reference

4 August 2017

22

1 reference

4 August 2017

373-384

1 reference

4 August 2017

4

1 reference

The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling

4 August 2017

1 reference

Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B.

21 January 2018

1 reference

Missing links in GSK3 regulation.

21 January 2018

1 reference

Expression analysis of glycogen synthase kinase-3 in human tissues.

21 January 2018

1 reference

Integrin-linked kinase (ILK): a "hot" therapeutic target

21 January 2018

1 reference

Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3beta.

21 January 2018

1 reference

Phosphorylation of tau by glycogen synthase kinase 3beta in intact mammalian cells influences the stability of microtubules

21 January 2018

1 reference

Glycogen synthase kinase-3beta regulates presenilin 1 C-terminal fragment levels

21 January 2018

1 reference

Low GSK-3 activity in frontal cortex of schizophrenic patients.

21 January 2018

1 reference

21 January 2018

The renaissance of GSK3

1 reference

Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes

21 January 2018

1 reference

Structure of GSK3beta reveals a primed phosphorylation mechanism

21 January 2018

1 reference

Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition

21 January 2018

1 reference

The structure of phosphorylated GSK-3beta complexed with a peptide, FRATtide, that inhibits beta-catenin phosphorylation

21 January 2018

1 reference

Glycogen synthase kinase 3 phosphorylation of different residues in the presence of different factors: analysis on tau protein.

21 January 2018

1 reference

Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin

21 January 2018

1 reference

A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation

21 January 2018

1 reference

Identification of the Axin and Frat binding region of glycogen synthase kinase-3.

21 January 2018

1 reference

GSK3, a master switch regulating cell-fate specification and tumorigenesis

21 January 2018

1 reference

Current therapies and emerging targets for the treatment of diabetes

21 January 2018

1 reference

The role of protein phosphorylation in human health and disease. The Sir Hans Krebs Medal Lecture.

21 January 2018

1 reference

Different expression of glycogen synthase kinase-3beta between young and old rat brains after transient middle cerebral artery occlusion.

21 January 2018

1 reference

Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3.

21 January 2018

1 reference

Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons.

21 January 2018

1 reference

Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells

21 January 2018

1 reference

A molecular mechanism for the effect of lithium on development

21 January 2018

1 reference

Lithium therapy and signal transduction.

21 January 2018

1 reference

Lithium inhibits caspase 3 activation and dephosphorylation of PKB and GSK3 induced by K+ deprivation in cerebellar granule cells

21 January 2018

1 reference

Lithium inhibits glycogen synthase kinase-3 by competition for magnesium.

21 January 2018

1 reference

Lithium reduces tau phosphorylation: effects in living cells and in neurons at therapeutic concentrations.

21 January 2018

1 reference

Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration.

21 January 2018

1 reference

The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3.

21 January 2018

1 reference

Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen

21 January 2018

1 reference

21 January 2018

1 reference

Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent

21 January 2018

1 reference

Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation

21 January 2018

1 reference

Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity

21 January 2018

1 reference

Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25.

21 January 2018

1 reference

Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest

21 January 2018

1 reference

Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases

21 January 2018

1 reference

Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?

21 January 2018

1 reference

3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3).

21 January 2018

1 reference

Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription

21 January 2018

1 reference

Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphatase and phosphoenolypyruvate carboxykinase gene expression

21 January 2018

1 reference

Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death

21 January 2018

1 reference

GSK-3 inhibition by adenoviral FRAT1 overexpression is neuroprotective and induces Tau dephosphorylation and beta-catenin stabilisation without elevation of glycogen synthase activity

21 January 2018

1 reference

Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists

21 January 2018

1 reference

Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons.

21 January 2018

1 reference

Arylimino-1,2,4-thiadiazolidinones: a new family of potassium channel openers

21 January 2018

1 reference

N-Benzylpiperidine derivatives of 1,2,4-thiadiazolidinone as new acetylcholinesterase inhibitors

21 January 2018

1 reference

Non-cholinergic pharmacotherapy approaches to the future treatment of Alzheimer's disease

21 January 2018

1 reference

Identification of sequence variants and analysis of the role of the glycogen synthase kinase 3 beta gene and promoter in late onset Alzheimer's disease.

21 January 2018

1 reference

Molecular cloning and characterization of the human glycogen synthase kinase-3beta promoter

21 January 2018

1 reference

The molecular bases of Alzheimer's disease and other neurodegenerative disorders

21 January 2018

1 reference

Glycogen synthase kinase-3beta is a negative regulator of cardiomyocyte hypertrophy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MED.10011

1 reference

4 August 2017

1 reference

PubMed ID

12111750